CN106075303A - A kind of Chinese medicine treating the postoperative emboli syndrome of hepatocarcinoma TACE - Google Patents
A kind of Chinese medicine treating the postoperative emboli syndrome of hepatocarcinoma TACE Download PDFInfo
- Publication number
- CN106075303A CN106075303A CN201610565492.8A CN201610565492A CN106075303A CN 106075303 A CN106075303 A CN 106075303A CN 201610565492 A CN201610565492 A CN 201610565492A CN 106075303 A CN106075303 A CN 106075303A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- radix
- postoperative
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/748—Oldenlandia or Hedyotis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8966—Fritillaria, e.g. checker lily or mission bells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9064—Amomum, e.g. round cardamom
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to pharmaceutical technology field, be specifically related to a kind of Chinese medicine treating the postoperative emboli syndrome of hepatocarcinoma TACE.This Chinese medicine is made up of the raw material of Chinese medicine medicine of following weight portion: 48 parts of Radix Glycyrrhizae, the Rhizoma Pinelliae 5 13 parts, 5 13 parts of Poria, 5 13 parts of Semen Armeniacae Amarum, Radix Paeoniae Rubra 48 parts, Pericarpium Citri Reticulatae 48 parts, Fructus Schisandrae Chinensis 48 parts, Bulbus Fritillariae Thunbergii 48 parts, Radix Curcumae 8 16 parts, Rhizoma Corydalis 8 16 parts, Herba Scutellariae Barbatae 8 16 parts, Herba Hedyotidis Diffusae 8 16 parts, Fructus Amomi 5 13 parts, Radix Salviae Miltiorrhizae 11 19 parts, peninjau gardenia 26 parts.All medicines and conjunction, play invigorating the spleen and relieving depression of liver-QI, clear fall lung stomach, upper and lower, the merit of blood circulation promoting and blood stasis dispelling, dispelling phlegm and alleviating pain that is in harmonious proportion altogether.The postoperative emboli syndrome of Hepatic cancer can be improved.
Description
Technical field
The invention belongs to pharmaceutical technology field, be specifically related to a kind of Chinese medicine treating the postoperative emboli syndrome of hepatocarcinoma TACE.
Background technology
China is the country that whole world onset of liver cancer rate is the highest and death toll is most, during most of patients finds during hepatocarcinoma to be
In late period, be the first-selected treatment of current late primary liver cancer patient's non-operative treatment through conduit hepatic intraarterial chemotherapy Embolization (TACE)
Method, but the postoperative thromboembolism Post-operative syndrome having 93.4% patient's generation in various degree of TACE, show as heating, hepatalgia, vomit
Tell, the symptom such as gastrointestinal reaction.Western medicine gives symptomatic treatment, and several drugs is used simultaneously, and symptom is difficult to full relief sometimes, no
Only affect the quality of life of patient, also have influence on next step TACE.
Summary of the invention
In order to solve above-mentioned technical problem, the invention provides a kind for the treatment of in the postoperative emboli syndrome of hepatocarcinoma TACE
Medicine.
The present invention is to be realized by following technical scheme:
A kind of Chinese medicine treating the postoperative emboli syndrome of hepatocarcinoma TACE, is made up of the raw material of Chinese medicine medicine of following weight portion:
Radix Glycyrrhizae 4-8 part, Rhizoma Pinelliae 5-13 part, Poria 5-13 part, Semen Armeniacae Amarum 5-13 part, Radix Paeoniae Rubra 4-8 part, Pericarpium Citri Reticulatae 4-8 part, Fructus Schisandrae Chinensis 4-8
Part, Bulbus Fritillariae Thunbergii 4-8 part, Radix Curcumae 8-16 part, Rhizoma Corydalis 8-16 part, Herba Scutellariae Barbatae 8-16 part, Herba Hedyotidis Diffusae 8-16 part, Fructus Amomi 5-13
Part, Radix Salviae Miltiorrhizae 11-19 part, peninjau gardenia 2-6 part.
Preferably, the Chinese medicine of the above-mentioned postoperative emboli syndrome for the treatment of hepatocarcinoma TACE, by the raw material of Chinese medicine of following weight portion
Medicine forms:
Radix Glycyrrhizae 5-7 part, Rhizoma Pinelliae 7-11 part, Poria 7-11 part, Semen Armeniacae Amarum 7-11 part, Radix Paeoniae Rubra 5-7 part, Pericarpium Citri Reticulatae 5-7 part, Fructus Schisandrae Chinensis 5-7
Part, Bulbus Fritillariae Thunbergii 5-7 part, Radix Curcumae 10-14 part, Rhizoma Corydalis 10-14 part, Herba Scutellariae Barbatae 10-14 part, Herba Hedyotidis Diffusae 10-14 part, Fructus Amomi
7-11 part, Radix Salviae Miltiorrhizae 13-17 part, peninjau gardenia 3-5 part.
It is furthermore preferred that the Chinese medicine of the above-mentioned postoperative emboli syndrome for the treatment of hepatocarcinoma TACE, the Chinese medicine by following weight portion is former
Material medicine composition:
6 parts of Radix Glycyrrhizae, the Rhizoma Pinelliae 9 parts, 9 parts of Poria, 9 parts of Semen Armeniacae Amarum, Radix Paeoniae Rubra 6 parts, Pericarpium Citri Reticulatae 6 parts, Fructus Schisandrae Chinensis 6 parts, Bulbus Fritillariae Thunbergii 6 parts, Radix Curcumae
12 parts, Rhizoma Corydalis 12 parts, Herba Scutellariae Barbatae 12 parts, Herba Hedyotidis Diffusae l2 part, Fructus Amomi 9 parts, Radix Salviae Miltiorrhizae 15 parts, peninjau gardenia 4 parts.
In Basic Theories of Chinese Medicine, liver controlling conveyance and dispersion, liver and peripheral region thereof are caused pathology row to damage, more affect by TACE operation
The function of liver controlling conveyance and dispersion.Thus the syndromes such as heating, nausea and vomiting, hepatalgia, abdominal distention, appetite difference occur.The present invention's
Treatment the postoperative emboli syndrome of hepatocarcinoma TACE Chinese medicine in, Radix Glycyrrhizae and in, control at taste, help it to lift.Rhizoma Pinelliae regulating the stomach and sending down the abnormal ascending QI, controls
Help it to drop at stomach.Poria spleen invigorating eliminating dampness by diuresis, Fructus Amomi removing dampness is amusing, and controls and helps at spleen it to rise.Four tastes and conjunction and nurse one's health the taste day after tomorrow,
Help its source of generating QI and blood, evil with Fuzheng Yiliu.Pericarpium Citri Reticulatae, Semen Armeniacae Amarum, Bulbus Fritillariae Thunbergii, enter edema caused by disorder of QI, and lung heat clearing is regulated the flow of vital energy, eliminating phlegm and lowering adverse QI.Radix Paeoniae Rubra, five
Taste, Radix Curcumae, Rhizoma Corydalis, enter Liver Channel blood system, removing heat from the liver, and soothing the liver liter falls into, and holds concurrently with flat gallbladder.Herba Scutellariae Barbatae enters lung, liver, kidney channel, heat clearing away
Removing toxic substances, blood stasis dispelling diuresis, Herba Hedyotidis Diffusae heat-clearing and toxic substances removing.Herba Hedyotidis Diffusae is sweet, light, cool, enters stomach, large intestine, small intestine meridian, heat clearing away solution
Poison, inducing diuresis to remove edema, promoting blood circulation and stopping pain.Radix Salviae Miltiorrhizae GUIXIN, Liver Channel, stasis-dispelling and pain-killing, promoting blood circulation to restore menstrual flow, clear away heart-fire relieving restlessness;GUIXIN, lung, tri-jiao channel.
Peninjau gardenia GUIXIN, lung, tri-jiao channel, pathogenic fire purging relieving restlessness, clearing away heat and promoting diuresis, removing pathogenic heat from blood and toxic substance from the body.Why parching to brown, is to strengthen its burnt bitter in taste acting on the heart
Effect, lets out effect of heart-fire.Because of emboli syndrome simulataneous insufficiency and excessive after TACE surgery, stagnation of QI-blood, for its domination of pathogen part, need
Its son is rushed down dirty by mother child relation, the raw heart-fire of edema with the liver involved, liver is female, and the heart is son, and liver has excess-fire, not only wants eliminating pathogen in the liver, eliminating heart-fire of also should holding concurrently,
Then liver-fire is easily clear, therefore takes peninjau gardenia and comes down in torrents heart-fire with thorough removing heat from the liver.All medicines and conjunction, play invigorating the spleen and relieving depression of liver-QI, clear fall lung stomach, tune altogether
With upper and lower, blood circulation promoting and blood stasis dispelling, the merit of dispelling phlegm and alleviating pain, making stomach fall and kind receive, spleen rises and kind mill, and liver rises and blood is the most strongly fragrant, and lung fall and gas are not
Stagnant, heart kidney therefore hands over Thailand's (regulation between water and fire), the mechanism of qi of all internal organs disorders, thus its lifting multiple is often, and disease can be to the most also.
Clinical test results shows, the Chinese medicine of the postoperative emboli syndrome for the treatment of hepatocarcinoma TACE of the present invention, the abdomen for the treatment of group
Bitterly, generate heat, vomit the persistent period and be all shorter than matched group (P < 0.05), the quality of life improvement coefficient of stabilization relatively matched group for the treatment of group
Significantly improve (P < 0.01), postoperative 7th day glutamate pyruvate transaminase (ALT) for the treatment of group, glutamic oxaloacetic transaminase, GOT (AST) and total bilirubin
(TBIL) within more postoperative 2nd day, significantly improving (P < 0.01), ALT, AST improve curative effect and are better than matched group (P < 0.05).Invention
The Chinese medicine of the postoperative emboli syndrome for the treatment of hepatocarcinoma TACE can improve the postoperative emboli syndrome of Hepatic cancer.
Detailed description of the invention
Below in conjunction with specific embodiment, the present invention is further described, in order to those skilled in the art knows more about
The present invention, but and it is not so limited the present invention.
Embodiment 1
A kind of Chinese medicine treating the postoperative emboli syndrome of hepatocarcinoma TACE, is made up of following raw material of Chinese medicine medicine:
6 parts of Radix Glycyrrhizae, the Rhizoma Pinelliae 9 parts, 9 parts of Poria, 9 parts of Semen Armeniacae Amarum, Radix Paeoniae Rubra 6 parts, Pericarpium Citri Reticulatae 6 parts, Fructus Schisandrae Chinensis 6 parts, Bulbus Fritillariae Thunbergii 6 parts, Radix Curcumae
12 parts, Rhizoma Corydalis 12 parts, Herba Scutellariae Barbatae 12 parts, Herba Hedyotidis Diffusae l2 part, Fructus Amomi 9 parts, Radix Salviae Miltiorrhizae 15 parts, peninjau gardenia 4 parts.
Embodiment 2
A kind of Chinese medicine treating the postoperative emboli syndrome of hepatocarcinoma TACE, is made up of following raw material of Chinese medicine medicine:
5 parts of Radix Glycyrrhizae, the Rhizoma Pinelliae 11 parts, 7 parts of Poria, 11 parts of Semen Armeniacae Amarum, Radix Paeoniae Rubra 5 parts, Pericarpium Citri Reticulatae 7 parts, Fructus Schisandrae Chinensis 5 parts, Bulbus Fritillariae Thunbergii 7 parts, strongly fragrant
Gold 10 parts, Rhizoma Corydalis 14 parts, Herba Scutellariae Barbatae 10 parts, Herba Hedyotidis Diffusae 14 parts, Fructus Amomi 7 parts, Radix Salviae Miltiorrhizae 17 parts, peninjau gardenia 5 parts.
Embodiment 3
A kind of Chinese medicine treating the postoperative emboli syndrome of hepatocarcinoma TACE, is made up of following raw material of Chinese medicine medicine:
7 parts of Radix Glycyrrhizae, the Rhizoma Pinelliae 7 parts, 11 parts of Poria, 7 parts of Semen Armeniacae Amarum, Radix Paeoniae Rubra 7 parts, Pericarpium Citri Reticulatae 5 parts, Fructus Schisandrae Chinensis 7 parts, Bulbus Fritillariae Thunbergii 5 parts, Radix Curcumae
14 parts, Rhizoma Corydalis 10 parts, Herba Scutellariae Barbatae 14 parts, Herba Hedyotidis Diffusae 10 parts, Fructus Amomi 11 parts, Radix Salviae Miltiorrhizae 13 parts, peninjau gardenia 3 parts.
Embodiment 4
A kind of Chinese medicine treating the postoperative emboli syndrome of hepatocarcinoma TACE, is made up of following raw material of Chinese medicine medicine:
4 parts of Radix Glycyrrhizae, the Rhizoma Pinelliae 13 parts, 5 parts of Poria, 13 parts of Semen Armeniacae Amarum, Radix Paeoniae Rubra 4 parts, Pericarpium Citri Reticulatae 8 parts, Fructus Schisandrae Chinensis 4 parts, Bulbus Fritillariae Thunbergii 8 parts, strongly fragrant
Gold 8 parts, Rhizoma Corydalis 16 parts, Herba Scutellariae Barbatae 8 parts, Herba Hedyotidis Diffusae 16 parts, Fructus Amomi 5 parts, Radix Salviae Miltiorrhizae 19 parts, peninjau gardenia 6 parts.
Embodiment 5
A kind of Chinese medicine treating the postoperative emboli syndrome of hepatocarcinoma TACE, is made up of following raw material of Chinese medicine medicine:
8 parts of Radix Glycyrrhizae, the Rhizoma Pinelliae 5 parts, 13 parts of Poria, 5 parts of Semen Armeniacae Amarum, Radix Paeoniae Rubra 8 parts, Pericarpium Citri Reticulatae 4 parts, Fructus Schisandrae Chinensis 8 parts, Bulbus Fritillariae Thunbergii 4 parts, Radix Curcumae
16 parts, Rhizoma Corydalis 8 parts, Herba Scutellariae Barbatae 16 parts, Herba Hedyotidis Diffusae 8 parts, Fructus Amomi 13 parts, Radix Salviae Miltiorrhizae 11 parts, peninjau gardenia 2 parts.
The Chinese medicine of the embodiment of the present invention 1 has been carried out clinical pharrnacokinetics test, and concrete condition is as follows:
1 data and method
1.1 physical data
Select Patients with Primary 160 example, be primary hepatocarcinoma (HCC) patient without operative treatment indication, age 29-85
Year, the median age 62 years old, wherein treatment group and each 80 examples of matched group.Treatment group female 15 example, male 45 examples;Matched group female 20 example, man
40 examples, two groups of Ka Shi mark all more than 60 points, and Child-Pugh classification is in A level or B level.Two groups of patients the age, sex,
Child-Pugh classification, Ka Shi scoring aspect comparing difference not statistically significant (P > 0.05), have comparability.
1.2 diagnosis and exclusion standards
Meet clinical diagnosis and the staging scale of hepatocarcinoma Professional Committee of Chinese Anti-Cancer Association primary hepatocarcinoma;Meet the suitable of TACE
Should demonstrate,prove;Anticipated life cycle >=3 month;Patient's muscle power situation is fair, and Karnofsky marks >=60 points.Exclusion standard: have TACE to prohibit
Avoid card;Research process merges and uses other Chinese medicines, affect observation index and judge;Through informed consent not by regulation medication, or
The congruent judgement person that affects the treatment of data.
1.3 method
1.3.1 TACE method patient lies supine DSA bed, selects right common femoral artery after bilateral inguinal district routine disinfection, drape, local anaesthesia
Puncture approach, inserts 5F-catheter sheath after puncturing successfully, select 5F-RH conduit selectivity to be inserted to coeliac trunk, common hepatic artery radiography.
Observe tumor feeding situation.Microtubular super-selective is inserted to blood supply of tumor, radiography display tumor staining sign.Clearly lead
Behind pipe position, with iodized oil (LP) 10mL, add lobaplatin 50mg, Perarubicin (THP) 30mg, add polidocanol 5mL and blend together emulsifying agent,
Take 10mL emulsifying agent row chemoembolization, give appropriate PVA particulate embolization, parallel postoperative radiography.Art finishes tube drawing, at right femoral artery puncture
Sterilizing bandaging after hemostasis by compression.
1.3.2 the administrated method chemoembolization postoperative same day, two groups are all supplemented glucose and normal saline, the secondary class of cephalo
Antibiotic prophylaxis infects and conventional liver protection treatment.The postoperative three degree of vomiter intramuscular injection metoclopramide 20mg of TACE, four degree of vomiters
Intravenous injection ondansetron 8mg;Generate heat less than 39 DEG C persons, and ice compress is brought down a fever, more than 39 DEG C persons, and oral indomethacin 25mg, after 4h
Body temperature fall person not yet, intramuscular injection compound aminophenazone 2mL or intravenous injection dexamethasone 5~10mg;Abdominal part moderate pain person
Oral indomethacin 25mg, severe pain person applies dolantin pain relieving.Treatment group on the basis for the treatment of of control group, the postoperative 1st
It adds with the Chinese medicine of the embodiment of the present invention 1, decocting extracting juice 150mL, 2 sub-services every day, is total to 7d the course for the treatment of.
1.4 observation item
Acute and the subacute reaction grade scale by WHO anticarcinogen, observes and records chemoembolization postoperative two groups of patients heating, liver
District's pain, nausea and vomiting symptom variation.Judge its degree and duration.Liver function grade: glutamic oxaloacetic transaminase, GOT (AST), paddy third
Transaminase (ALT), total bilirubin (TBil) utilize full automatic biochemical apparatus to detect in the 2nd day after surgery and the 7th day.
1.5 quality of life efficacy assessment standards
China has worked out a draft in nineteen ninety with reference to external index, according to appetite, spirit, sleep, tired, pain, family
Front yard understand with coordinate, the understanding worked together with coordinate, self is to the understanding of cancer, the attitude to treating, daily life, the pair for the treatment of
The scoring of the project such as effect, facial expression, quality of life full marks are 60 points, quality of life extreme difference be < 20 points, differ from for 20-30
Point, generally 31-40 divides, and preferably divides for 41-50, and good divides for 51-60.Improve after treatment: after treatment, scoring is than treatment
Front increase >=10 point;Decline: after treatment, scoring reduces >=10 points than before treatment;Stable: scoring increase and decrease person within 10 points.Stable
Rate=(raising number of cases+stablize number of cases)/total number of cases × 100%.
1.6 statistical method
Using statistic software SPSS 13.0 to process data, measurement data uses mean ± standard deviation (x ± s) to represent, group
Between compare employing t inspection, enumeration data adopts and is expressed as a percentage, and between group, contrast uses chi-square criterion.System is had for difference with P < 0.05
Meaning learned by meter.
2 results
After 2.1 liang of group patient TACE, clinical symptoms and sign persistent period and quality of life compare
The stomachache for the treatment of group, generate heat, persistent period of vomitting all is shorter than matched group, two groups of statistically significant (P < of comparing difference
0.05).Quality of life comparitive study after two groups of treatments, treatment group is respectively with matched group quality of life improvement coefficient of stabilization
93.75%, 56.25%, two groups of comparing differences statistically significant (P < 0.01).It is shown in Table 1.
Before and after 2.2 liang of group treatments, liver function compares
Treatment group and postoperative 2nd day liver function comparing difference not statistically significant (P > 0.05) of matched group;Treatment group and matched group
In each group, postoperative 7th day ALT, AST and TBIL value has height statistical significance (P < with postoperative 2nd day comparing difference respectively
0.01);Treatment group ALT, AST relatively matched group substantially reduces (P < < 0.05).Two groups of total bilirubin comparing differences are anticipated without statistics
Justice (P > 0.05).It is shown in Table 2.
Claims (3)
1. treat a Chinese medicine for the postoperative emboli syndrome of hepatocarcinoma TACE, be made up of the raw material of Chinese medicine medicine of following weight portion:
Radix Glycyrrhizae 4-8 part, Rhizoma Pinelliae 5-13 part, Poria 5-13 part, Semen Armeniacae Amarum 5-13 part, Radix Paeoniae Rubra 4-8 part, Pericarpium Citri Reticulatae 4-8 part, Fructus Schisandrae Chinensis 4-8
Part, Bulbus Fritillariae Thunbergii 4-8 part, Radix Curcumae 8-16 part, Rhizoma Corydalis 8-16 part, Herba Scutellariae Barbatae 8-16 part, Herba Hedyotidis Diffusae 8-16 part, Fructus Amomi 5-13
Part, Radix Salviae Miltiorrhizae 11-19 part, peninjau gardenia 2-6 part.
The Chinese medicine of the postoperative emboli syndrome for the treatment of hepatocarcinoma TACE the most according to claim 1, it is characterised in that by weighing as follows
The raw material of Chinese medicine medicine composition of amount part:
Radix Glycyrrhizae 5-7 part, Rhizoma Pinelliae 7-11 part, Poria 7-11 part, Semen Armeniacae Amarum 7-11 part, Radix Paeoniae Rubra 5-7 part, Pericarpium Citri Reticulatae 5-7 part, Fructus Schisandrae Chinensis 5-7
Part, Bulbus Fritillariae Thunbergii 5-7 part, Radix Curcumae 10-14 part, Rhizoma Corydalis 10-14 part, Herba Scutellariae Barbatae 10-14 part, Herba Hedyotidis Diffusae 10-14 part, Fructus Amomi
7-11 part, Radix Salviae Miltiorrhizae 13-17 part, peninjau gardenia 3-5 part.
The Chinese medicine of the postoperative emboli syndrome for the treatment of hepatocarcinoma TACE the most according to claim 2, it is characterised in that by weighing as follows
The raw material of Chinese medicine medicine composition of amount part:
6 parts of Radix Glycyrrhizae, the Rhizoma Pinelliae 9 parts, 9 parts of Poria, 9 parts of Semen Armeniacae Amarum, Radix Paeoniae Rubra 6 parts, Pericarpium Citri Reticulatae 6 parts, Fructus Schisandrae Chinensis 6 parts, Bulbus Fritillariae Thunbergii 6 parts, Radix Curcumae
12 parts, Rhizoma Corydalis 12 parts, Herba Scutellariae Barbatae 12 parts, Herba Hedyotidis Diffusae l2 part, Fructus Amomi 9 parts, Radix Salviae Miltiorrhizae 15 parts, peninjau gardenia 4 parts.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610565492.8A CN106075303A (en) | 2016-07-19 | 2016-07-19 | A kind of Chinese medicine treating the postoperative emboli syndrome of hepatocarcinoma TACE |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610565492.8A CN106075303A (en) | 2016-07-19 | 2016-07-19 | A kind of Chinese medicine treating the postoperative emboli syndrome of hepatocarcinoma TACE |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106075303A true CN106075303A (en) | 2016-11-09 |
Family
ID=57220660
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610565492.8A Pending CN106075303A (en) | 2016-07-19 | 2016-07-19 | A kind of Chinese medicine treating the postoperative emboli syndrome of hepatocarcinoma TACE |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106075303A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106334165A (en) * | 2016-11-28 | 2017-01-18 | 广西慧投互联网金融服务有限公司 | Traditional Chinese medicine composition capable of nursing esophagus cancer |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103721196A (en) * | 2014-01-11 | 2014-04-16 | 赵雨溪 | Traditional Chinese medicine composition for treating liver cancer |
CN103721230A (en) * | 2013-12-28 | 2014-04-16 | 李清元 | Traditional Chinese medicinal composition for treating liver cancer |
CN103800827A (en) * | 2014-01-24 | 2014-05-21 | 刘璐 | Traditional Chinese medicine for treating liver cancer |
CN104606494A (en) * | 2014-12-17 | 2015-05-13 | 广东食品药品职业学院 | Traditional Chinese medicine for treating liver cancer and preparation method thereof |
-
2016
- 2016-07-19 CN CN201610565492.8A patent/CN106075303A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103721230A (en) * | 2013-12-28 | 2014-04-16 | 李清元 | Traditional Chinese medicinal composition for treating liver cancer |
CN103721196A (en) * | 2014-01-11 | 2014-04-16 | 赵雨溪 | Traditional Chinese medicine composition for treating liver cancer |
CN103800827A (en) * | 2014-01-24 | 2014-05-21 | 刘璐 | Traditional Chinese medicine for treating liver cancer |
CN104606494A (en) * | 2014-12-17 | 2015-05-13 | 广东食品药品职业学院 | Traditional Chinese medicine for treating liver cancer and preparation method thereof |
Non-Patent Citations (1)
Title |
---|
刘城林 等: "中药对肝动脉栓塞化疗所致肝损害的疗效观察", 《中国中西医结合杂志》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106334165A (en) * | 2016-11-28 | 2017-01-18 | 广西慧投互联网金融服务有限公司 | Traditional Chinese medicine composition capable of nursing esophagus cancer |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104547502B (en) | A kind of Chinese medicine composition for treating Sjogren syndrome | |
CN103623338A (en) | Traditional Chinese medicine granule for treating side effects on alimentary canal after cancer chemotherapy and preparation method thereof | |
CN102423393B (en) | Traditional Chinese medicinal composition for treating qi stagnation and blood stasis type primary dysmenorrhea | |
CN106075303A (en) | A kind of Chinese medicine treating the postoperative emboli syndrome of hepatocarcinoma TACE | |
CN102895371B (en) | Traditional Chinese medicine for treating diarrhea type irritable bowel syndrome | |
CN101036741A (en) | Medicine for treating cancer and preparing method therefor | |
CN105125701A (en) | Plaster for treating deficiency-cold irritable bowel syndrome type diarrhea | |
CN105126030A (en) | Zhuang medicine composition assisted in resisting lung cancer | |
CN101095790A (en) | Chinese traditional medicine composition for treating anxiety disease and method of making the same | |
CN105617335A (en) | Radix bupleurum Xianxiong decoction capable of improving bile reflux gastritis after cancer chemoradiotherapy | |
Shi et al. | Effect of Chinese drugs combining with chemotherapy on quality of life in 146 children with solid tumor | |
CN105214067A (en) | A kind of medicine for the treatment of cancer patients diarrhoea | |
CN102743670B (en) | Traditional Chinese medicinal qi regulating soup used for functional delayed gastric emptying after stomach operation | |
CN1217680C (en) | Repellent mixture for department of gynecology | |
CN115998824B (en) | Traditional Chinese medicine composition for clearing damp and detoxicating, and preparation method and application thereof | |
CN103877471B (en) | Traditional Chinese medicinal composition for treating porcine viral diarrhea and preparation method thereof | |
CN102327587B (en) | Traditional Chinese herbal medicine for curing chronic or intractable immune thrombocytopenia and preparation method of Traditional Chinese medicine preparation | |
CN106039001A (en) | Probiotic fermentation Chinese herbal compound composition for treating breast cancer and preparation method and application thereof | |
CN106214977A (en) | A kind of treat dysphagic Chinese medicine composition | |
CN105748718A (en) | Pharmaceutic preparation for treating recurrent spontaneous abortion caused by blocking antibody deficiency | |
CN105497637B (en) | A kind of Chinese materia medica preparation for treating metabolic syndrome | |
CN104840645A (en) | Traditional Chinese medicine for treating dizziness | |
CN114042142A (en) | Traditional Chinese medicine for treating chronic diarrhea and preparation method thereof | |
CN104689154A (en) | Nursing medicine for treating postpartum fever | |
CN104189870A (en) | Traditional Chinese medicine for treating allergic asthma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20161109 |